Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 7;23(1):401.
doi: 10.1186/s12933-024-02496-5.

Associations of physiologic subtypes based on HOMA2 indices of β-cell function and insulin sensitivity with the risk of kidney function decline, cardiovascular disease, and all-cause mortality from the 4C study

Peiqiong Luo  1   2 , Danpei Li  1   2 , Yaming Guo  1   2 , Xiaoyu Meng  1   2 , Ranran Kan  1   2 , Limeng Pan  1   2 , Yuxi Xiang  1   2 , Beibei Mao  1   2 , Yi He  1   2 , Siyi Wang  1   2 , Yan Yang  1   2 , Zhelong Liu  1   2 , Junhui Xie  1   2 , Benping Zhang  1   2 , Wentao He  1   2 , Shuhong Hu  1   2 , Xinrong Zhou  1   2 , Xuefeng Yu  3   4
Affiliations

Associations of physiologic subtypes based on HOMA2 indices of β-cell function and insulin sensitivity with the risk of kidney function decline, cardiovascular disease, and all-cause mortality from the 4C study

Peiqiong Luo et al. Cardiovasc Diabetol. .

Abstract

Background: Previous studies have been limited by their inability to differentiate between the effects of insulin sensitivity and β-cell function on the risk of kidney function decline, cardiovascular disease (CVD), and all-cause mortality. To address this knowledge gap, we aimed to investigate whether the physiological subtypes based on homeostasis model assessment-2 (HOMA2) indices of β-cell function (HOMA2-B) and insulin sensitivity (HOMA2-S) could be used to identify individuals with subsequently high or low of clinical outcome risk.

Methods: This retrospective cohort study included 7,317 participants with a follow-up of up to 5 years. Based on HOMA2 indices, participants were categorized into four physiologic subtypes: the normal phenotype (high insulin sensitivity and high β-cell function), the insulinopenic phenotype (high insulin sensitivity and low β-cell function), the hyperinsulinaemic phenotype (low insulin sensitivity and high β-cell function), and the classical phenotype (low insulin sensitivity and low β-cell function). The outcomes included kidney function decline, CVD events (fatal and nonfatal), and all-cause mortality. Cox regression models were used to calculate hazard ratios (HRs) for outcomes, and spline models were used to examine the dose-dependent associations of HOMA2-B and HOMA2-S with outcomes.

Results: A total of 1,488 (20.3%) were classified as normal, 2,179 (29.8%) as insulinopenic, 2,173 (29.7%) as hyperinsulinemic, and 1,477 (20.2%) as classical subtypes. Compared with other physiological subtypes, the classical subtype presented the highest risk of kidney function decline (classical vs. normal HR 11.50, 95% CI 4.31-30.67). The hyperinsulinemic subtype had the highest risk of CVD and all-cause mortality (hyperinsulinemic vs. normal: fatal CVD, HR 6.56, 95% CI 3.09-13.92; all-cause mortality, HR 4.56, 95% CI 2.97-7.00). Spline analyses indicated the dose-dependent associations of HOMA2-B and HOMA2-S with outcomes.

Conclusions: The classical subtype had the strongest correlation with the risk of kidney function decline, and the hyperinsulinemic subtype had the highest risk of CVD and all-cause mortality, which should be considered for interventions with precision medicine.

Keywords: All-cause mortality; CVD events; HOMA2-B; HOMA2-S; Kidney function decline.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart of the cohort study CVD cardiovascular disease, CKD chronic kidney disease, HOMA2 homeostatic model assessment-2
Fig. 2
Fig. 2
Distributions of HOMA2-B, HOMA2-S, and corresponding physiological subtypes based on HOMA2 indices of β-cell function and insulin sensitivity. The HOMA2 computational model was used to calculate insulin sensitivity (HOMA2-S, %) and beta-cell function (HOMA2-B, %) based on fasting glucose and insulin values. Each dot represents a person. Participants were grouped into four subtypes including normal, insulinopenic, hyperinsulinemic, and classical subtypes. High and low HOMA2-S and HOMA2-B were defined as being above or below the median values (HOMA2-S: 165.0 and HOMA2-B: 63.6).A: Distribution of HOMA2-B, HOMA2-S, and corresponding physiological subtypes based on HOMA2 indices of β-cell function and insulin sensitivity was presented in subgroups of different glucose statuses (A). B–D: Distributions of HOMA2-B, HOMA2-S, and corresponding physiological subtypes based on HOMA2 indices of β-cell function and insulin sensitivity were presented in all participants (B), NGT (C), and prediabetes (D) respectively.HOMA2 homeostatic model assessment-2, NGT normal glucose status-2
Fig. 3
Fig. 3
Frequency of outcomes according to physiologic subtypes based on HOMA2 indices of β-cell function and insulin sensitivity in all participants
Fig. 4
Fig. 4
Forest plot showing the adjusted HRs of physiological subtypes based on HOMA2 indices of β-cell function and insulin sensitivity for kidney function decline in all participants and participants with NGT and prediabetes
Fig. 5
Fig. 5
Forest plot showing the adjusted HRs of physiological subtypes based on HOMA2 indices of β-cell function and insulin sensitivity for CVD events and all-cause mortality in all participants and participants with NGT and prediabetes. The model was adjusted for age, sex, BMI, SBP, FPG, HbA1c, TC, LDL-C, TG, ALT, GGT, eGFR, smoking status, drinking status, hypotensive drug, and lipid-lowering drug. HOMA2 homeostatic model assessment-2, HR hazard ratio, CI confidence interval, NGT normal glucose status, CVD cardiovascular disease
Fig. 6
Fig. 6
RCS showing the dose-response relationships of HOMA2-B and HOMA2-S with the risk of kidney function decline, fatal CVD events, nonfatal CVD events, and all-cause mortality The dose-response relationships of HOMA2-B with the risk of kidney function decline (A for the MDRD method,B for the CKD-EPI method), fatal CVD events (C), nonfatal CVD events (D), and all-cause mortality (E). The dose-response relationships of HOMA2-B with the risk of kidney function decline (F for the MDRD method,G for the CKD-EPI method), fatal CVD events (H), nonfatal CVD events (I), and all-cause mortality (J). RCS restricted cubic spline, HOMA2 homeostatic model assessment-2, MDRD Modification of Diet in Renal Disease, CKD-EPI the Chronic Kidney Disease Epidemiology Collaboration, CVD cardiovascular disease
See this image and copyright information in PMC

References

    1. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease Lancet. 2017;389(10075):1238–52. - PubMed
    1. Kishi S, Kadoya H, Kashihara N. Treatment of chronic kidney disease in older populations. Nat Rev Nephrol. 2024. - PubMed
    1. Chen N, Ma LL, Zhang Y, Chu X, Dong J, Yan YX. Association of long-term triglyceride-glucose index patterns with the incidence of chronic kidney disease among non-diabetic population: evidence from a functional community cohort. Cardiovasc Diabetol. 2024;23(1):7. - PMC - PubMed
    1. Kazancioglu R. Risk factors for chronic kidney disease: an update. Kidney Int Suppl (2011). 2013;3(4):368–71. - PMC - PubMed
    1. Flora GD, Nayak MK. A brief review of Cardiovascular diseases, Associated Risk factors and current treatment regimes. Curr Pharm Des. 2019;25(38):4063–84. - PubMed

Publication types

MeSH terms

LinkOut - more resources